Rapid traversal of vast chemical space using machine learning-guided docking screens.

Journal: Nature computational science
PMID:

Abstract

The accelerating growth of make-on-demand chemical libraries provides unprecedented opportunities to identify starting points for drug discovery with virtual screening. However, these multi-billion-scale libraries are challenging to screen, even for the fastest structure-based docking methods. Here we explore a strategy that combines machine learning and molecular docking to enable rapid virtual screening of databases containing billions of compounds. In our workflow, a classification algorithm is trained to identify top-scoring compounds based on molecular docking of 1 million compounds to the target protein. The conformal prediction framework is then used to make selections from the multi-billion-scale library, reducing the number of compounds to be scored by docking. The CatBoost classifier showed an optimal balance between speed and accuracy and was used to adapt the workflow for screens of ultralarge libraries. Application to a library of 3.5 billion compounds demonstrated that our protocol can reduce the computational cost of structure-based virtual screening by more than 1,000-fold. Experimental testing of predictions identified ligands of G protein-coupled receptors and demonstrated that our approach enables discovery of compounds with multi-target activity tailored for therapeutic effect.

Authors

  • Andreas Luttens
    Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, BMC, Uppsala, Sweden. aluttens@mit.edu.
  • Israel Cabeza de Vaca
    Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, BMC, Uppsala, Sweden.
  • Leonard Sparring
    Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, BMC, Uppsala, Sweden.
  • José Brea
    Grupo de Investigación "BioFarma" USC, Centro de Investigación CIMUS, Planta 3ª, Avd. de Barcelona s/n, 15782 Santiago de Compostela, Spain. pepo.brea@usc.es.
  • Antón Leandro Martínez
    Innopharma Drug Screening and Pharmacogenomics Platform, BioFarma research group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain.
  • Nour Aldin Kahlous
    Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, BMC, Uppsala, Sweden.
  • Dmytro S Radchenko
    Enamine Ltd., Kyiv, Ukraine.
  • Yurii S Moroz
    Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
  • María Isabel Loza
    Grupo de Investigación "BioFarma" USC, Centro de Investigación CIMUS, Planta 3ª, Avd. de Barcelona s/n, 15782 Santiago de Compostela, Spain. mabel.loza@usc.es.
  • Ulf Norinder
    Swetox, Unit of Toxicology Sciences , Karolinska Institutet , Forskargatan 20 , SE-151 36 Södertälje , Sweden.
  • Jens Carlsson
    Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, BMC, Uppsala, Sweden. jens.carlsson@icm.uu.se.